Mouse Anti-HIV-1 gp41 Recombinant Antibody (clone 1583) (CAT#: PABZ-068)

Figure 1 Neutralization by S1/env/3 monoclonal antibodies

The S1/env/3 and HIV-1 neutralizing activity of the ascites from four hybridomas was determined. Results are expressed as the reciprocal of the mAb ascitic fluid dilution giving>90% reduction in HIV-1 titre, or neutralizing 100 TCID50 units of S1/env/3.

Evans, D. J., McKeating, J., Meredith, J. M., Burke, K. L., Katrak, K., John, A., ... & Almond, J. W. (1989). An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. Nature, 339(6223), 385.

Figure 2 Staining of HIV-infected and uninfected cells by mAbs to gp41 cytoplasmic domain.

HIV-1-infected H9 cells either pretreated (---) or not (···) with sCD4 and uninfected H9 cells (···) were incubated fluoreehrome conjugated second antibody alone (—) or with the antibodies shown at a d dilution of either 1/120 for ascites or a concentration of 30 μg/ml for purified immunoglobulin for 2 hr at 4° with agitation, washed, and then fixed. After a further wash the cells were labeled with phycoerythrin-coupled second antibodies and then analyzed by flow cytometry on a FACScan using Consort 30 software. Each peak represents the accumulation of 10,000 gated events. Note that the staining of uninfected and HIV-infected cells with mAbs 1583 and 1908 is superimposed in this experiment.

Sattentau, Q. J., Zolla-Pazner, S., & Poignard, P. (1995). Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology, 206(1), 713-717.